Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

J.P. Morgan Raise Invitrogen to 'Overweight'

J.P. Morgan upgraded Invitrogen (IVGN) to overweight from neutral.

Analyst Chris Shibutani says he strongly thinks Invitrogen's plans to acquire Molecular Probes will re-accelerate growth in Invitrogen's molecular biology business and provide meaningful accretion to earnings in 2003 and 2004. He believes Molecular Probes' revenue should benefit significantly from a substantial improvement in distribution capabilities with Invitrogen.

Shibutani says even with Wednesday's stock price increase, the shares still trade at a discount to re-agent supplier peers, a discount that he finds unwarranted.

blog comments powered by Disqus